Is There a Low-Grade Precursor Pathway in Breast Cancer?

被引:16
作者
King, Tari A. [1 ]
Sakr, Rita A. [1 ]
Muhsen, Shirin [1 ]
Andrade, Victor P. [1 ]
Giri, Dilip [2 ]
Van Zee, Kimberly J. [1 ]
Morrow, Monica [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
CARCINOMA-IN-SITU; COMPARATIVE GENOMIC HYBRIDIZATION; DUCTAL CARCINOMA; LOBULAR CARCINOMA; GENETIC PATHWAYS; RISK-FACTORS; PROGRESSION; EVOLUTION; HYPERPLASIA; MANAGEMENT;
D O I
10.1245/s10434-011-2053-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Newly proposed models of breast tumorigenesis suggest that low- and high-grade lesions have distinct tumor progression pathways. Our objective was to examine the relationship between histologic grade and molecular subtype in women with lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) who developed subsequent ipsilateral invasive breast cancers. Methods. Patients who underwent surveillance for classical LCIS (1994-2007) and those followed after lumpectomy +/- radiation for DCIS (1991-2004) who developed subsequent ipsilateral invasive cancers and had available tissue blocks were included. ER/PR/HER2 surrogates were used for molecular subtype. Results. Material was available for 27 patients with classical LCIS who developed ipsilateral invasive cancer (12 invasive ductal cancer [IDC], 14 invasive lobular, 1 mixed), and 26 patients with DCIS (12 low-grade [LG], 14 high-grade [HG]) who developed ipsilateral IDC. No difference in age at diagnosis or median time to invasive cancer existed between groups with LCIS and DCIS. When stratified by grade, 0 of 12 LG-DCIS developed LG-IDC (3 grade II; 9 grade III), and only 1 of 12 LCIS patients who developed IDC had LG-IDC. Thirteen (93%) patients with HG-DCIS developed HG-IDC. In contrast, molecular subtype was maintained in 23 of 27 (85%) cases of LCIS and in 18 of 26 (69%) cases of DCIS. Conclusions. These data do not support a low-grade precursor pathway characterized by LCIS and LG-DCIS. ER/PR and HER2 status have a high rate of concordance between in situ and subsequent invasive lesions. Additional studies of metachronous in situ and invasive lesions are needed to better understand pathways of breast tumorigenesis.
引用
收藏
页码:1115 / 1121
页数:7
相关论文
共 25 条
[1]   Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution [J].
Allred, D. Craig ;
Wu, Yun ;
Mao, Sufeng ;
Nagtegaal, Iris D. ;
Lee, Sangjun ;
Perou, Charles M. ;
Mohsin, Syed K. ;
O'Connell, Peter ;
Tsimelzon, Anna ;
Medina, Dan .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :370-378
[2]  
Allred DC, 2010, DIS BREAST, P321
[3]   Molecular Grading of Ductal Carcinoma In situ of the Breast [J].
Balleine, Rosemary L. ;
Webster, Lucy R. ;
Davis, Sean ;
Salisbury, Elizabeth L. ;
Palazzo, Juan P. ;
Schwartz, Gordon F. ;
Cornfield, Dennis B. ;
Walker, Robert L. ;
Byth, Karen ;
Clarke, Christine L. ;
Meltzer, Paul S. .
CLINICAL CANCER RESEARCH, 2008, 14 (24) :8244-8252
[4]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[5]  
Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO
[6]  
2-B
[7]   Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution [J].
Buerger, H ;
Mommers, EC ;
Littmann, R ;
Simon, R ;
Diallo, R ;
Poremba, C ;
Dockhom-Dworniczak, B ;
van Diest, PJ ;
Boecker, W .
JOURNAL OF PATHOLOGY, 2001, 194 (02) :165-170
[8]   RISK-FACTORS FOR BREAST-CANCER IN WOMEN WITH PROLIFERATIVE BREAST DISEASE [J].
DUPONT, WD ;
PAGE, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (03) :146-151
[9]   Genetic pathways in the evolution of breast ductal carcinoma in situ [J].
Farabegoli, F ;
Champeme, MH ;
Bieche, I ;
Santini, D ;
Ceccarelli, C ;
Derenzini, M ;
Lidereau, R .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :280-286
[10]   Pathologic findings from the national surgical adjuvant breast and bowel project - Twelve-year observations concerning lobular carcinoma in situ [J].
Fisher, ER ;
Land, SR ;
Fisher, B ;
Mamounas, E ;
Gilarski, L ;
Wolmark, N .
CANCER, 2004, 100 (02) :238-244